Stay updated on Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check21 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.9%
- Check28 days agoNo Change Detected
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check64 days agoChange DetectedThe web page has been updated to reflect a new version of the study protocol for a clinical trial involving pembrolizumab and Imprime PGG for non-small cell lung cancer, with significant changes in the study's collaborators and the revision number.SummaryDifference54%
- Check71 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check78 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.